Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence Technology Innovation Award
Acura received the Award for its proprietary Limitx™ Technology, which is intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.
This Frost & Sullivan Award recognized Acura for its innovative approach to addressing the most prevalent forms of opioid abuse and which offers the potential to become an industry standard. In selecting Acura,
To read the full report, visit www.acurapharm.com.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking results, performance, or achievements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the
for Acura Investor Relations
Email contactMedia -
Email contact(416) 644-2020 or (514) 939-3989
News Provided by Acquire Media